Latest Insider Transactions at Ngm Biopharmaceuticals Inc (NGM)
This section provides a real-time view of insider transactions for Ngm Biopharmaceuticals Inc (NGM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NGM BIOPHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NGM BIOPHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2024
|
Column Group Gp, LP > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,000
+50.0%
|
-
|
|
Apr 05
2024
|
Column Group Gp, LP > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,640,080
-100.0%
|
-
|
|
Apr 05
2024
|
Column Group Gp, LP > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,103,333
-100.0%
|
-
|
|
Apr 05
2024
|
Tcg Opportunity Iii Gp, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
1,000
+50.0%
|
-
|
|
Apr 05
2024
|
Tcg Opportunity Iii Gp, LLC > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,640,080
-100.0%
|
-
|
|
Apr 05
2024
|
Tcg Opportunity Iii Gp, LLC > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,103,333
-100.0%
|
-
|
|
Apr 05
2024
|
David V Goeddel Director |
BUY
Other acquisition or disposition
|
Indirect |
1,000
+50.0%
|
-
|
|
Apr 05
2024
|
David V Goeddel Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
21,874,413
-100.0%
|
-
|
|
Apr 05
2024
|
David V Goeddel Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
134,180
-100.0%
|
-
|
|
Apr 05
2024
|
Column Group L P Director |
BUY
Other acquisition or disposition
|
Indirect |
1,000
+50.0%
|
-
|
|
Apr 05
2024
|
Column Group L P Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,640,080
-100.0%
|
-
|
|
Apr 05
2024
|
Column Group L P Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,103,333
-100.0%
|
-
|
|
Apr 05
2024
|
David J Woodhouse Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
97,654
-100.0%
|
-
|
|
Apr 05
2024
|
David J Woodhouse Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
23,993
-100.0%
|
-
|
|
Apr 05
2024
|
Jean Frederic Viret Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
3,038
-100.0%
|
-
|
|
Apr 05
2024
|
William Jl Rieflin |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,769,168
-100.0%
|
-
|
|
Apr 05
2024
|
William Jl Rieflin |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,172
-100.0%
|
-
|
|
Apr 05
2024
|
Valerie L Pierce |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,458
-100.0%
|
-
|
|
Apr 05
2024
|
Suzanne Sawochka Hooper |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
7,000
-100.0%
|
-
|
|
Apr 05
2024
|
Irene Perlich Principal Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,284
-100.0%
|
-
|
|
Apr 05
2024
|
Hsiao D Lieu Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,349
-100.0%
|
-
|
|
Jan 16
2024
|
David J Woodhouse Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,032
-9.0%
|
$13,032
$1.34 P/Share
|
|
Jan 16
2024
|
Valerie L Pierce |
SELL
Payment of exercise price or tax liability
|
Direct |
5,021
-8.31%
|
$5,021
$1.34 P/Share
|
|
Jan 16
2024
|
Irene Perlich Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,025
-10.25%
|
$1,025
$1.34 P/Share
|
|
Jan 16
2024
|
Hsiao D Lieu Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,430
-9.1%
|
$5,430
$1.34 P/Share
|
|
Nov 16
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
17,520
+0.61%
|
$0
$0.62 P/Share
|
|
Nov 16
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
5,840
+0.61%
|
$0
$0.62 P/Share
|
|
Nov 16
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Direct |
1,460
+1.08%
|
$0
$0.62 P/Share
|
|
Nov 15
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
50,373
+1.75%
|
$0
$0.71 P/Share
|
|
Nov 15
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
16,791
+1.75%
|
$0
$0.71 P/Share
|
|
Nov 15
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Direct |
2,720
+2.01%
|
$0
$0.71 P/Share
|
|
Mar 02
2023
|
Mangini Siobhan Nolan President and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
76,000
+50.0%
|
-
|
|
Mar 02
2023
|
Jin Long Chen Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,000
+6.17%
|
-
|
|
Mar 02
2023
|
Hsiao D Lieu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,000
+48.8%
|
-
|
|
Mar 02
2023
|
David J Woodhouse Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
127,200
+46.76%
|
-
|
|
Mar 02
2023
|
Valerie L Pierce |
BUY
Grant, award, or other acquisition
|
Direct |
49,000
+46.82%
|
-
|
|
Jan 31
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
530,190
+16.01%
|
$2,650,950
$5.0 P/Share
|
|
Jan 31
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
176,730
+16.01%
|
$883,650
$5.0 P/Share
|
|
Jan 30
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
22,626
+0.99%
|
$113,130
$5.0 P/Share
|
|
Jan 30
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
7,542
+0.99%
|
$37,710
$5.0 P/Share
|
|
Jan 23
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
29,700
+1.32%
|
$148,500
$5.0 P/Share
|
|
Jan 23
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
9,900
+1.32%
|
$49,500
$5.0 P/Share
|
|
Jan 20
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
1,500
+0.07%
|
$7,500
$5.0 P/Share
|
|
Jan 20
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
500
+0.07%
|
$2,500
$5.0 P/Share
|
|
Jan 19
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
112,917
+4.89%
|
$564,585
$5.0 P/Share
|
|
Jan 19
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
37,639
+4.89%
|
$188,195
$5.0 P/Share
|
|
Jan 17
2023
|
Jin Long Chen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
85,082
-8.56%
|
$425,410
$5.15 P/Share
|
|
Jan 17
2023
|
Jin Long Chen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,082
+7.88%
|
$85,082
$1.44 P/Share
|
|
Jan 12
2023
|
Column Group L P Director |
BUY
Open market or private purchase
|
Indirect |
16,134
+0.77%
|
$64,536
$4.95 P/Share
|
|
Jan 12
2023
|
David V Goeddel Director |
BUY
Open market or private purchase
|
Indirect |
5,378
+0.77%
|
$21,512
$4.95 P/Share
|